Acute coronary syndromes: morbidity, mortality, and pharmacoeconomic burden

Area of Science:

• Cardiology
• Public Health

Background:

• Acute coronary syndromes (ACS), including myocardial infarction (MI), represent a significant cause of morbidity and mortality.
• Despite treatment advances, ACS affects 1.5 million hospital discharges annually, with substantial economic impact exceeding $150 billion.
• High rehospitalization rates (20% within 1 year) contribute significantly to ACS-related costs.

Purpose of the Study:

• To analyze the drivers of morbidity, mortality, and costs associated with ACS.
• To evaluate the impact of early revascularization and stenting on survival rates in ACS patients.
• To assess current evidence-based and emerging guidelines for invasive versus conservative ACS treatment strategies.

Main Methods:

• Review of evidence regarding early revascularization and stenting in ACS.
• Analysis of current practice guidelines for ACS management.
• Evaluation of predictors for optimal medical therapy and post-discharge mortality.

Main Results:

• Evidence suggests early revascularization and stenting impact ACS survival rates.
• Guidelines offer varying perspectives on invasive versus conservative ACS treatment approaches.
• Identifying predictors of optimal medical therapy and mortality is crucial for managed care.

Conclusions:

• Suboptimal evidence-based management of ACS persists, necessitating improved strategies.
• Understanding disease drivers is essential for reducing ACS burden.
• Healthcare providers play a vital role in optimizing ACS treatment for efficiency, safety, and cost-effectiveness.